{
    "symbol": "URGN",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 14:48:09",
    "content": " These may include statements regarding our ongoing commercialization activities relating to Jelmyto, our ongoing and planned research efforts and clinical trials, the potential benefits of Jelmyto and our product candidates, data presentations, regulatory filings, future revenue opportunities, potentially reaching cash flow breakeven by 2025, the availability of the second tranche of our term loan facility, and 2022 financial guidance, among other things. Research and Development expenses for the second quarter ended June 30, 2022 were $12.6 million compared to $30.1 million for the same period in 2021. For the second quarter ended June 30, 2022, we reported financing expense related to prepaid forward obligations to RTW investment of $5.8 million compared to $3.1 million for the same period in 2021. As previously mentioned, we continue to anticipate full year 2022 net product revenues from Jelmyto to be in the range of $70 million to $80 million, representing a 46% to 67% increase over 2021. We  our anticipated full year 2022 operating expense guidance to stand in the range of $130 million to $140 million, including non-cash share-based compensation expenses of $10 million to $16 million, subject to market conditions."
}